Uncategorized - SciBase

The annual general meeting resolved:

to adopt the profit and loss statement and the balance sheet and the group profit and loss statement and the group balance sheet for the financial year 2020;

that SEK 175,081,224 shall be carried forward in new account and that no dividend shall be paid;

to grant the board members and the CEO discharge from liability for the financial year 2020;

that the board of directors shall consist of four ordinary members without deputy members and that a registered accounting firm shall be elected as auditor;

that the fees payable to the board of directors for the period until the end of the next annual general meeting shall be SEK 200,000 for the chairman of the board and SEK 150,000 to each of the other ordinary board members (who are not employed by a larger shareholder in the Company)and that fees payable to the auditor is to be paid in accordance with approved invoices;

for the period until the end of the next annual general meeting, to re-elect Diana Ferro, Thomas Taapken and Tord Lendau and to new-elect Dr. Matt Leavitt as board members, to re-elect Tord Lendau as chairman of the board of directors and to re-elect the auditing firm PricewaterhouseCoopers AB (PwC) as auditor for the Company, with Magnus Lagerberg as auditor-in-charge;

to adopt principles for the appointment of a nomination committee (same principles as previous year); and

to authorize the board of directors to increase the share capital through issuance of new shares, warrants and/or convertible debentures through which the Company’s share capital may be increased by an amount corresponding to not more than 20 per cent of the share capital after such issue(s);

For more information, please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com

Certified Advisor (CA):

Avanza

Tel: +46 8 409 421 20

Email: corp@avanza.se

The information was submitted, through the agency of the contact person set out above, for publication at the time stated by Scibase´s news distributor Cision upon publication of this press release.

About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed and sells a unique point-of-care device for evaluation of skin disorders such as skin cancer and atopic dermatitis. Its first product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and inflammation. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies and abnormalities. SciBase is listed on First North Growth Market (“SCIB”). Further information is available at www.scibase.com.

SciBase’s strategy is to leverage the Nevisense technology platform to launch additional clinical applications and products. The first clinical application or indication to be added is NMSC, initially for Nevisense 3.0.

There are two types of skin cancer: melanoma and non-melanoma skin cancer (NMSC). NMSC is more than ten times more prevalent than melanoma and comes itself in primarily two forms: basal cell carcinoma and squamous cell carcinoma. Although NMSC is less harmful and deadly than melanoma, it is still important that it is detected early and is managed with the most appropriate therapy. Because Dermatologists see many more patients with suspected non-melanoma skin cancer than suspected melanoma, there is potential for greatly increased use of Nevisense. SciBase estimates that the global potential for the use of diagnostic devices such as Nevisense for this indication could exceed 4 million tests annually. Adding the NMSC application to the current melanoma application potential of 5-7 million annual tests increases the market opportunity substantially for SciBase.

The development of the NMSC application has been driven by a demand from the German customer base and is an important part of our continued growth in Germany. Recent publications support the use of Nevisense in NMSC. A study published in November 2020 by Sarac, Garbe and others confirmed the ability of Nevisense to accurately identify non-melanoma skin cancers. In the study Nevisense showed good discriminative power to distinguish NMSC from benign lesions and concluded that Nevisense can support clinicians in the early diagnosis of NMSC.

The NMSC application is a software update and as such can be easily deployed to almost all existing Nevisense users. It also uses the same Nevisense electrode and business model as melanoma. The first step in the launch is to update the existing customer base, initially in Germany.

“The launch of the NMSC application is a key part of our growth strategy. The demand from our German customer base has been the driver behind the development. As the current melanoma reimbursement in Germany should also apply to NMSC we expect increased electrode usage by existing customers and increased appeal to new customers given they will be able to use the system on a larger patient base. 2021 looks to be an exciting year for SciBase with a number of milestones already reached, and plenty more to come” says Simon Grant, CEO of SciBase.

For more information please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com

Certified Advisor:
Avanza
Tel: +46 8 409 421 20
Email: ca@avanza.se

About SciBase and Nevisense
SciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.

MDR is a set of mandatory legal requirements central for all companies selling medical devices in the EU. The new regulation comes into effect on May 26^th. SciBase is one of very few medical device manufacturers to have completed the MDR certification, after an intensive two year process. With the MDR Certification in place SciBase can release new products, indications and functionality such as their new Non-melanoma Skin cancer (NMSC) application.

The MDR was introduced by the European Union to establish a modernized and more robust legislative framework for medical devices. The aim is to ensure better protection of public health and patient safety by improving the quality, safety and performance of medical devices.

Until now, Medical devices have been CE-marked through the MDD (Medical Device Directive). Following various incidents such as the PIP breast implant scandal in France, the EU decided to improve safety and control by strengthening the regulation of medical devices. The result is the MDR industry regulations.

MDR tightens the control mechanisms for medical devices, including medical software and Apps and will have substantial impact on medical device manufacturers and distributors.

“Achieving MDR has been a strategically important goal for SciBase, because MDR is necessary for us to add new applications such as NMSC (Non-Melanoma Skin Cancer) to our platform – which is key to our strategy. For customers this will result in better products. For the industry this raises the bar in terms of what it takes to operate in this space. This has been a challenging project for SciBase, where parts of the process that were out of our hands didn’t progress as we expected; but we made it in the end. I believe many companies will struggle to achieve certification and so we believe MDR certification will be a competitive advantage going forward. Overall, it is another milestone as we execute our strategy to provide our customers with additional clinical applications using our unique technology platform” says Simon Grant, CEO of SciBase.

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 16.00 CET on May 10, 2021.

For more information please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com

Certified Advisor:
Avanza
Tel: +46 8 409 421 20
Email: ca@avanza.se

In October 2020, SciBase was granted a Category III CPT® (CPT III) code from the American Medical Association (AMA) for the Nevisense melanoma detection test. This was the first step in the process to receive reimbursement coverage in the U.S.

The application submission for Medicare coverage in Florida marks an important step in the reimbursement process for SciBase. The application was submitted to the Medicare Administrative Contractor (MAC) covering Florida, First Coast Service Options (FCSO). A positive decision may be reached as early as the second half of 2021, which would significantly broaden the early melanoma detection market opportunity throughout Florida, where SciBase has a well-established user base. It is estimated that around 10,000 invasive melanomas will be diagnosed in Florida in the coming year which represents 10% of the total in the US. The biopsies performed to find these melanomas are in the hundreds of thousands.

"Coverage from CMS is critical for new tests such as ours, so this first submission is a major milestone for SciBase and for Nevisense in the U.S.," said Simon Grant, CEO of SciBase. "Medicare coverage in Florida presents a significant opportunity for SciBase as there are nearly 5 million Medicare beneficiaries in the state. It also provides an opportunity to expand within our partner Advanced Dermatology and Cosmetic Surgery group’s (ADCS) network of 70 Florida clinics. It is symbolic that we submitted the application on Melanoma Monday and at the start of Skin Cancer Awareness month in the US. We believe that Nevisense can play a central role in improving the quality of skin cancer detection in the U.S., and especially so in the patient demographic covered by Medicare.”

For more information please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com

Certified Advisor:
Avanza
Tel: +46 8 409 421 20
Email: ca@avanza.se

Recent concerns over the magnitude of COVID-19's effect on the timely detection and management skin cancers led Dr. Matt Leavitt and Dr. James Solomon of ADCS to participate in research that was published in the January 19, 2021 edition of the Journal of the American Academy of Dermatology (JAAD). Additionally, Dr. Solomon and Dr. Murray Cotter also participated in research that demonstrated the effectiveness of total-body skin cancer exams, which was published in the Journal of Clinical Oncology®, an American Society of Clinical Oncology (ASCO) Journal.

ADCS currently integrates Nevisense during routine total body skin cancer exams to offer their patients the most advanced technology for the earliest possible detection of melanoma. Melanoma is the deadliest and most aggressive form of skin cancer, but when detected early, treatment has a nearly 100% cure rate. Providing patients with Nevisense for early testing further supports ADCS’ and SciBase’s continued commitment to improving outcomes for both patients and providers.

“In our recent research published in JAAD, we saw the significant negative effect that COVID 19 has had on the rates of skin cancer diagnosis. The later skin cancer is diagnosed, the more difficult it is to treat. This makes it even more important to encourage people to get their skin cancer examinations as soon as possible,” said Dr. Matt Leavitt, Executive Chairman and Founder of Advanced Dermatology and Cosmetic Surgery.

Skin Cancer Statistics

Skin cancer is the most common cancer in the United States and worldwide.
More people are diagnosed with skin cancer each year in the U.S. than all other cancers combined.
Over 90% of melanomas are associated to UV radiation exposure from the sun and tanning beds
Having 5 or more sunburns doubles your risk for melanoma.
Melanoma is almost 100% curable if detected early.
The number of new melanoma cases diagnosed is estimated to increase by almost 6% in 2021 in the U.S.
The number of melanoma deaths is expected to increase by almost 5% in 2021 in the U.S.
It is estimated that 207,390 new cases of melanoma, 101,280 noninvasive (in situ) and 106,110 invasive, will be diagnosed in the U.S. in 2021.
1 in 5 Americans will develop skin cancer by the age of 70.
More than 2 people dies of skin cancer in the U.S. every hour.

“We know that our Nevisense system plays an important role in the early detection of melanoma, and we are very happy to work with ADCS in raising awareness of the importance of early detection. Hopefully, we can encourage those reluctant to visit a clinic due to the pandemic, to go ahead and book their total body skin exams,” said Simon Grant, CEO of SciBase.

For more information, please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com

Certified Advisor:
Avanza
Tel: +46 8 409 421 20
Email: corpt@avanza.se

About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed and sells a unique point-of-care device for evaluation of skin disorders such as skin cancer and atopic dermatitis. Its first product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and inflammation. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies and abnormalities. SciBase is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.

About Advanced Dermatology and Cosmetic Surgery

Advanced Dermatology and Cosmetic Surgery is the largest dermatology practice in the country. We are committed to providing comprehensive and unparalleled dermatologic and aesthetic care in a welcoming and engaging environment, seeking to make each patient experience unique. We strive to combine the best of the art of medicine with the latest advances in research and technology in formulating individualized treatment plans to achieve the desired result with superior patient safety and privacy standards. To learn more about Advanced Dermatology, visit www.advancedderm.com or call 1-866-400-DERM.

The nominating committee, consisting of Christer Jönsson (appointed by FourierTransorm), Iraj Arastoupour, Peter Elmvik and Tord Lendau Chairman of the Board, hereby proposes the election of Dr. Matt Leavitt as a new member of the Board to the 2021 AGM.

Dr. Leavitt, Executive Chairman, former CEO and Founder of Advanced Dermatology and Cosmetic Surgery (ADCS) is a board-certified Dermatologist and hair restoration/hair loss specialist. He is recognized both nationally and internationally as an accomplished physician, surgeon, educator, clinical researcher, lecturer, author and humanitarian.

With his clinical background and unique commercial experience in building the US’s largest Dermatology practice group, the Nominating Committee believes that Dr Leavitt can play a central role in guiding the strategy of SciBase in the US. SciBase’s current US focus is on securing coverage from payors and marketing to Dermatology practice groups; both areas where the Nominating Committee also sees Matt's knowledge and experience as being of great benefit to SciBase.

The Nominating Committee has previously proposed the re-election of all current board members, with the exception of Barbro Fridén, who has declined re-election.

More information on Dr. Matt Leavitt can be found here: https://www.advancedderm.com/about-us/news/dr-matt-leavitt-profiled-in-orlando-business-journal or here https://www.advancedderm.com/about-us/leadership/dr-matt-leavitt .

For more information please contact:
Tord Lendau, Chairman of the Board
Tel: +46 708 10 01 67
Email: tordlendau@hotmail.com

Certified Advisor:
Avanza
Tel: +46 8 409 421 20
Email: ca@avanza.se

The information was submitted, through the agency of the contact person set out above, for publication at the time stated by Scibase's news distributor Cision upon publication of this press release.

About SciBase and Nevisense
SciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.

As the previous published date for the interim report for the first quarter, May 13^th, is a national holiday, the date has now been changed to May 12^th.

The updated financial calendar is set out as follows:

May 12 Interim report Q1 2021

May 18 Annual general meeting 2021

August 19 Interim report Q2 2021

November 11 Interim report Q3 2021

For more information, please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com

Certified Advisor (CA):

Avanza

Tel: +46 8 409 421 20

Email: corp@avanza.se

About SciBase and Nevisense
SciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.

Notice

Shareholders wishing to participate at the meeting must:

(i) be entered in the shareholders' register, kept by Euroclear Sweden AB (the Swedish Central Securities Depository & Clearing Organisation), on the record day, which is Tuesday 4 June 2024, and

(ii) notify the Company of their attendance and any assistant no later than Friday 7 June 2024. Notification can be made in writing to Setterwalls Advokatbyrå AB, Attn: Eric Torstensson, P.O. Box 1050, SE-101 39 Stockholm, Sweden or by e-mail to eric.torstensson@setterwalls.se.

Notification shall include full name, personal identification number or corporate registration number, address, daytime telephone number and, if appropriate, information about representative, proxy, and assistants. The number of assistants may not be more than two. In order to facilitate entry to the meeting, notification should, where appropriate, be ac-companied by powers of attorney, registration certificates and other documents of authority.

Nominee registered shares

In order to be entitled to participate and vote at the meeting, shareholders who have their shares registered in the name of a nominee must have their shares registered in their own name, so that the shareholder will be included in the transcription of the share register as of Tuesday 4 June 2024. Such registration may be temporary (so-called voting rights registration) and is requested to the nominee in accordance with the nominee's routines at such time in advance as the nominee determines. Voting rights registrations made by the nominee no later than Friday 7 June 2024 will be taken into account in the preparation of the share register.

Postal voting

The board of directors has decided, pursuant to Chapter 7, Section 4a of the Swedish Companies Act and the Company's articles of association, to apply the possibility of postal voting in conjunction with the general meeting. A special form shall be used for postal voting. The form will be available on the Company's website, https://investors.scibase.se/en/governance/annual-general-meeting.

The form may be submitted by post to Setterwalls Advokatbyrå AB, Attn: Eric Torstensson, P.O. Box 1050, 101 39 Stockholm or via e-mail to eric.torstensson@setterwalls.se. The completed voting form must be received by Setterwalls Advokatbyrå AB no later than Wednesday 12 June 2024 provided the shareholder has given notice of attendance at the general meeting no later than Friday 7 June 2024. However, a complete postal vote which reaches Setterwalls Advokatbyrå AB no later than Friday 7 June 2024 shall also be considered the shareholder's notice of attendance at the meeting (by postal voting).

The shareholder may not provide special instructions or conditions in the voting form. If so, the vote (i.e. the postal vote in its entirety) is invalid. Further instructions and conditions are included in the form for postal voting.

Proxy voting

A shareholder represented by proxy shall issue a power of attorney which shall be dated and signed by the shareholder. If the shareholder postal votes by proxy, the power of attorney shall be enclosed to the form. If issued by a legal entity, the power of attorney shall also be accompanied by registration certificate or, if not applicable, equivalent documents of authority. Power of attorney forms will be available on the Company's website https://investors.scibase.se/en/annual-general-meeting-2024.

Processing of personal data

For information regarding how your personal data is processed in connection with the annual general meeting, please refer to the privacy policy on Euroclear Sweden AB's website, https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

Proposed agenda

Opening of the meeting and election of chairman of the meeting.
Preparation and approval of the voting list.
Approval of the agenda.
Election of one person who shall approve the minutes of the meeting.
Determination of whether the meeting has been duly convened.
Submission of the annual report and the auditor's report as well as of the consolidated financial statements and the auditor's report on the group.
Resolution in respect of:
1. adoption of the profit and loss statement and the balance sheet as well as of the consolidated profit and loss statement and the consolidated balance sheet;
2. allocation of the Company's results according to the adopted balance sheet; and
3. the members of the board of directors' and the CEO's discharge from liability.
Resolution regarding the number of members and, where applicable, deputies of the board of directors and number of auditors and, where applicable, deputy auditors.
Determination of the fees payable to the members of the board of directors and the auditors.
Election of members of the board of directors and auditor.
Resolution on principles for the appointment of a nomination committee.
Resolution on an authorisation for the board of directors to resolve upon issues of shares, warrants and convertibles.
Closing of the meeting.

The nomination committee's proposed resolutions

The nomination committee is composed of the chairman of the board of directors of the Company (i.e. Tord Lendau), Thomas Axelsson (appointed by Gell Group), Dharminder Chahal (appointed by VanHerk Group), and Peter Elmvik (appointed by Stockholms Elbolag). The nomination committee has presented the following proposed resolutions in relation to items 1 and 8-11 in the proposed agenda.

Item 1 - Election of chairman

Axel Helle (lawyer at Setterwalls Advokatbyrå AB) is proposed as chairman of the meeting, or if he is unable to attend the meeting, any other person proposed by the board of directors.

Items 8-10 - Resolution regarding the number and election of and remuneration to the board of directors and auditors

The nomination committee proposes that the board of directors, until the end of the next annual general meeting, shall consist of four (4) ordinary members without deputy members. Furthermore, it is proposed that a registered accounting firm shall be elected as auditor.

The nomination committee furthermore proposes that the fees payable to the board of directors for the period until the end of the next annual general meeting shall be SEK 200,000 for the chairman of the board and SEK 150,000 to each of the other ordinary board members (who are not employed by a larger shareholder in the Company). It is proposed that the Company's auditor shall be paid in accordance with approved invoices.

The board of directors today consists of the following five (5) ordinary members without deputy members: Tord Lendau (chairman), Diana Ferro, Thomas Taapken, Matt Leavitt och Jvalini Dwarkasing.

Tord Lendau has declined re-election after ten years as chairman of the board of directors. Matt Leavitt and Jvalini Dwarkasing have also declined re-election. However, Matt Leavitt will continue to assist the Company on a consultancy basis.

The nomination committee proposes that Diana Ferro and Thomas Taapken are re-elected and that Jesper Høiland and Robert Molander are new-elected as ordinary board members. Furthermore, Jesper Høiland is proposed to be new-elected as chairman of the board of directors.

The registered accounting firm PricewaterhouseCoopers AB (PwC) is proposed to be re-elected as auditor. The accounting firm has informed that Magnus Lagerberg will remain as principally responsible auditor.

The nomination committee has, as the basis for its proposal, regarding the composition of the board of directors, discussed the Company's future needs and reviewed the annual evaluation of the board of directors and its work and interviewed several candidates. The nomination committee has thoroughly discussed the requirements for competence, experience and background that are placed on the board of directors of Scibase, considering, among other things, the Company's strategic development, governance and control. Independence issues have been highlighted, as well as the requirement for versatility and breadth in the board. The nomination committee makes the assessment that the proposed board members, considering the Company's needs, operations, stage of development and other circumstances, would give the board of directors a good and appropriate composition.

Below is a summarized description of the proposed new board members' education, experience, other assignments, and independence. Further information about all proposed board members will be made available on the Company's website.

Jesper Høiland

Education: MSc and BSc, Copenhagen Business School.

Experience: Jesper has over 25 years of experience from senior positions in global pharmaceutical companies such as Ascendis Pharma (CCO), Radius Health (CEO) and Novo Nordisk (President and EVP for the US with a particular focus on pricing, product launches and infrastructure building). Jesper has previously been a board member of Concert Pharma and Leo Pharma. Jesper has lived and worked in the US, Switzerland, Denmark, Australia, France, Belgium and Canada for the past 30 years.

Other current assignments: Strategic advisor to pharmaceutical and medical device companies. Member of the board of directors and the audit committee of ALK.

Independence: Jesper is independent in relation to the Company and its management as well as to major shareholders.

Robert Molander

Education: MBA in Marketing and Finance, Washington University, John M. Olin School of Business and dual BA degrees in Economics and International Studies, Miami University.

Experience: Senior executive and advisor with over 25 years of expertise in life science commercialization, primarily based in the United States. Robert has successfully led companies such as Novartis, Pfizer, Shionogi, and Trialbee through product launches, business development and scaling commercial operations. Robert has previously been Chief Commercial Officer at Infant Bacterial Therapeutics AB and Trialbee AB and a board member of Infant Bacterial Therapeutics AB.

Other current assignments: Board member of Xspray Pharma AB, CEO of Stratfox Healthcare Group LLC.

Independence: Robert is independent in relation to the Company and its management and to major shareholders.

Item 11 - Resolution on principles for the appointment of a nomination committee

The nomination committee proposes the following decision for appointment of a nomination committee for the annual general meeting 2025 (same principles as the previous year). The nomination committee for the annual general meeting 2025, which shall be comprised of four members, shall be appointed by way of that the chairman of the board of directors will consult with the three largest shareholders of the Company at the end of the third quarter of 2024. These shareholders will be requested to each appoint one member who, together with the chairman of the board of directors, will form the nomination committee. The composition of the nomination committee shall be publicly announced no later than six months prior to the annual general meeting. The nomination committee, whose mandate period applies until the time a new nomination committee has constituted itself, shall appoint a chairman among its members. The nomination committee shall prior to the annual general meeting 2025 prepare and submit proposals regarding the election of the chairman of the annual general meeting, the number of board members and, where applicable, deputy members, the number of auditors and, where applicable, deputy auditors, the election of board members, chairman and, where applicable, deputy members, auditor and, where applicable, deputy auditors, remuneration for the board of directors and the auditor, as well as guidelines for the appointment of the nomination committee for the following annual general meeting. The nomination committee's proposals shall be presented in the notice to a general meeting where election of board members and auditor shall take place and on the Company's website. Should a member of the nomination committee resign from its assignment, a replacement shall be sought from the shareholder that appointed the departing member. Should a shareholder that has appointed a member of the nomination committee substantially decrease its ownership in the Company, the next shareholder in size order shall, if the nomination committee so resolves, be requested to appoint a member to the nomination committee.

The board of directors' proposed resolutions

The board of directors of the Company has presented the following proposed resolutions in relation to items 7(ii), and 12 in the proposed agenda.

Item 7 (ii) - Allocation of the Company's results according to the adopted balance sheet

The board of directors proposes that SEK 202,523,429 shall be carried forward in new account. Accordingly, no dividend is proposed.

Item 12 - Resolution regarding authorisation for the board of directors to resolve upon issues of shares, warrants and convertibles

The board of directors proposes that the annual general meeting resolves to authorize the board of directors to, until the next annual general meeting, on one or more occasions, decide upon issuances of new shares, issuance of warrants and/or convertibles. New issues of shares and issues of warrants and/or convertibles may occur with or without preferential rights for shareholders of the Company and may be made either in cash and/or by way of set-off or contribution in kind or otherwise be conditional. Through issuances resolved upon with support from the authorisation - with deviation from the shareholders' preferential rights - the number of shares issued, or number of shares created in connection with exercise of warrants or conversion of convertibles, shall correspond to not more than a 20 per cent dilution of the share capital and the number of shares and votes in the Company after such issue(s). The chairman of the board of directors, the CEO or a person appointed by the board of directors shall be authorized to make any minor adjustments required to register the resolution with the Swedish Companies Registration Office.

Majority requirements

Resolution in accordance with the board of director's proposal in accordance with item 12 on the agenda requires that the general meeting's resolution is supported by shareholders representing at least two thirds of the shares represented at the general meeting as well as of the votes cast.

Shareholders' right to request information

The board of directors and the CEO shall, if any shareholder so requests and the board of directors believe that it can be done without material damage to the Company, provide information regarding circumstances that may affect the assessment of an item on the agenda, of the Company's, or a subsidiary's economic situation and of the Company's relations with other group companies on the general meeting.

Documentation

The financial accounts and auditor's report will be kept available at the Company's office and on the Company's website www.scibase.com. Copies of such documents will be sent free of charge to shareholders who so request and state their postal address. The proposals of the board of directors and the nomination committee are set out in full in the notice.

Stockholm, May 2024

SciBase Holding AB (publ)

The board of directors

For more information, please contact:
Pia Renaudin, CEO SciBase
Tel: +46 73 206 98 02
Email: pia.renaudin@scibase.com

Certified Adviser:
Vator Securities
Tel: +46 8 580 065 99
Email: ca@vatorsec.se

The information was submitted, through the agency of the contact person set out above, for publication at the time stated by Scibase's news distributor Cision upon publication of this press release

About SciBase

SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com. All press releases and financial reports can be found here: https://investors.scibase.se/en/pressreleases.

Simon Grant, CEO of SciBase commented "This article shows just how important the skin and epithelial barrier in general, are in the development of a range of diseases. It also illustrates the potential value of tools for epithelial barrier assessment. This week Prof Akdis and his team in Davos also published an article in Allergy on the use of Nevisense with perhaps the most common barrier-related disease, atopic dermatitis. The Nature article is impressive in its breadth and by extension what it can mean for SciBase's barrier assessment technology. I think this will help followers of SciBase understand why we have included barrier assessment as a key component of our strategy. The article is not just important from a scientific perspective; we also believe it will, together with the previously published article in Allergy, drive interest from researchers and potential industry partners. "

Professor Akdis provides some background. "There has been a steep increase in allergic and autoimmune diseases, reaching epidemic proportions and now affecting more than one billion people worldwide. These diseases are more common in industrialized countries, and their prevalence continues to rise in developing countries in parallel to urbanization and industrialization. Intact skin and mucosal barriers are crucial for the maintenance of tissue homeostasis as they protect host tissues from infections, environmental toxins, pollutants and allergens.

A defective epithelial barrier has been demonstrated in allergic and autoimmune conditions such as asthma, atopic dermatitis, allergic rhinitis, chronic rhinosinusitis, eosinophilic esophagitis, coeliac disease and inflammatory bowel disease. In addition, leakiness of the gut epithelium is also implicated in systemic autoimmune and metabolic conditions such as diabetes, obesity, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis and autoimmune hepatitis. Finally, distant inflammatory responses due to a `leaky gut' and microbiome changes are suspected in Alzheimer disease, Parkinson disease, chronic depression and autism spectrum disorders.

The article introduces the `epithelial barrier hypothesis', which proposes that the increase in epithelial barrier-damaging agents linked to industrialization, urbanization and modern life underlies the rise in allergic, autoimmune and other chronic conditions. Furthermore, it discusses how the immune responses to impaired microbiota, which normally acts as a barrier against pathogens, may be involved in the development of these diseases.

The research started in 1998 with the first studies showing mechanisms of eczema, mechanisms of epithelial cell death and continued with more than 60 publications, many major discoveries and one ready to use skin barrier detection instrument.

The articles can be found at:

Nature article: https://www.nature.com/articles/s41577-021-00538-7 .

Allergy article: https://onlinelibrary.wiley.com/doi/10.1111/all.14842?af=R .

For more information please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com

Certified Advisor:
Avanza
Tel: +46 8 409 421 20
Email: ca@avanza.se

About SIAF-SFI

The Swiss Institute of Allergy and Asthma Research (SIAF) is a department of the foundation Swiss Research Institutes for High Altitude Climate and Medicine Davos (SFI), an affiliated institute of the University of Zurich, and member of the Life Science Zurich Graduate School. SIAF members play leading roles in national and international organizations, such as European Academy of Allergy and Clinical Immunology and in editorial boards and editorships of top Journals in the field of allergy asthma and clinical immunology. At the same time, SIAF fulfills teaching obligations in the University of Zurich. The research activities at SIAF are focused on patient-relevant translational research and the investigation of the immunological principles in the field of skin atopic dermatitis, allergies and asthma to develop approaches for new preventive and curative treatments for patients. SIAF also promotes personalized medicine to develop treatment approaches that are better tailored to the needs of individual patients. These personalized medicine research activities are expected to not only help to find tailor-made therapies but also to develop more precise diagnosis. The continuously growing SIAF is one of the most cited and leading institutes in its area worldwide with more than 50,000 citations and 1,000 original research articles in the last 20 years. SIAF organizes the internationally renowned World Immune Regulation Meeting (WIRM) in Davos every year. SIAF works in close collaboration with the Christine Kühne-Center for Allergy Research and Education (CK-CARE), Davos. Further information is available at www.siaf.uzh.ch.

As there are no outstanding questions, we expect that the internal process at the notified body will be finalized by the end of April thus delaying the certification process by two weeks from our expected date.

MDR is a set of mandatory legal requirements and central for all companies selling medical devices in the EU. The new regulation will come into force on the 26th of May this year.

"Unfortunately, Covid-19 and the extremely high pressure on all notified bodies from Companies has delayed our MDR certification by two weeks. This is both unexpected and highly frustrating after more than two years working on this project, but this part of the process is out of our hands. At this time we do not see a risk for further delay, but this final step lies with our notified body." says Simon Grant, CEO of SciBase.

For more information please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com

Certified Advisor:
Avanza
Tel: +46 8 409 421 20
Email: ca@avanza.se